Company newsCompany release
Pfizer PFE
Pfizer says ELREXFIO meets primary endpoint in Phase 3 myeloma study
The Phase 3 MagnetisMM-32 study tested ELREXFIO alone in adults with relapsed or refractory multiple myeloma who had prior anti-CD38 therapy and lenalidomide.
GetSignal
Free on iOS and Android
Pfizer announced topline results from the Phase 3 MagnetisMM-32 study on October 27, 2026, for ELREXFIO (elranatamab) given as monotherapy.
The study met its primary endpoint, and the company said ELREXFIO outperformed standard regimens.
Key facts
- Study
- MagnetisMM-32 (Phase 3)
- Drug
- ELREXFIO (elranatamab), monotherapy
- Patients
- Adults with relapsed or refractory multiple myeloma who received at least one prior line of anti-CD38 therapy and lenalidomide
- Result
- Met primary endpoint
Source: The company's release on Business Wire, October 27, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
More company news
Pfizer first, then the newest- Florida Power & Light doubles Saving Steps funding to $30 million
NEE · NextEra Energy · Company release ·